摘要
Mucin 1(Mucin 1,MUC 1)是一种广泛的糖基化的上皮跨膜蛋白,主要保护细胞免受外界环境的紧张作用。生理上,在应激状态下,MUC 1分离es进入MUC1-N和MUC1-C部分,导致向内存活信号的转导,这对维持细胞的功能至关重要。最近的研究提出了显著的相关性。MUC 1通过调节多种信号通路和细胞-细胞与细胞-基质相互作用,过度表达和扩增癌细胞的增殖和转移。已经证明了TMUC 1-细胞质结构域(MUC 1-CD)加速了对硼替佐米、曲豆单抗和他莫昔芬等几种抗癌药物的耐药性发展。此外,mUC 1-cd也是非法的。VED促进多药耐药(MDR)基因的表达,最终抑制MUC 1的表达,同时对人表皮生长因子受体2阳性(HER 2)α进行再敏感化。ND/或雌激素受体(ER)阳性的乳腺癌细胞分别对硼替佐米、曲妥珠单抗和他莫昔芬。本文就MUC 1原癌基因在癌细胞中的作用作一综述。活体、肿瘤进展和转移,然后继续提及MUC1诱导对目前市场上包括bor在内的各种治疗药物产生耐药的机制替佐米、曲妥珠单抗和他莫昔芬。
关键词: MUC 1-CD,乳腺癌,化疗耐药,转移,肿瘤传播。
图形摘要
Current Cancer Drug Targets
Title:Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Volume: 18 Issue: 8
关键词: MUC 1-CD,乳腺癌,化疗耐药,转移,肿瘤传播。
摘要: As an extensively glycosylated transmembrane protein of epithelium, Mucin1 (MUC1) mostly protects cells from tensions induced by external milieu. Physiologically, during stress condition, MUC1 separates into MUC1-N and MUC1-C moieties, resulting in transduction of inward survival signals, essential for maintaining cell's functionality. Recent studies have proposed a significant correlation between MUC1 overexpression and amplification of cancer cell’s proliferation and metastasis through modulation of multiple signaling pathways and cell-cell and cell-matrix interactions. It has been shown that MUC1- Cytoplasmic Domain (MUC1-CD) accelerates development of resistance to several anti-cancer therapeutic agents including bortezomib, trastuzumab and tamoxifen. Furthermore, MUC1-CD is also involved in promoting expression of multi drug resistance (MDR) genes and finally, silencing MUC1 expression was together with resensitization of human epidermal growth factor receptor 2 positive (HER2+) and/or estrogen receptor (ER+) positive breast cancer cells to bortezomib, trastuzumab and tamoxifen respectively. In this review, we briefly describe the role of MUC1 proto-oncogene in cancer cell’s survival, tumor progression and metastasis and then continue with mentioning the mechanisms through which MUC1 induce resistance to various currently existing therapeutic agents in market including bortezomib, trastuzumab and tamoxifen.
Export Options
About this article
Cite this article as:
Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents, Current Cancer Drug Targets 2018; 18 (8) . https://dx.doi.org/10.2174/1568009617666170623113520
DOI https://dx.doi.org/10.2174/1568009617666170623113520 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science Pharmacological Approaches for BRCA1/2 Related Breast and Ovarian Cancer: Preclinical Studies and Early Clinical Trials
Current Women`s Health Reviews Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Current Topics in Medicinal Chemistry A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Natural Plant Extracts as Potential Therapeutic Agents for the Treatment of Cancer
Current Topics in Medicinal Chemistry A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies
Current Medicinal Chemistry Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Nutriproteomics – Linking Proteomics Variation with Personalized Nutrition
Current Pharmacogenomics and Personalized Medicine Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Biomarkers, Critical Disease Pathways, Drug Targets, and Alternative Medicine in Male Breast Cancer
Current Drug Targets The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Familial Colorectal Cancer Type X
Current Genomics Actinomycetes as a Paramount Source of Biologically Important Enzyme Inhibitors – “A Boon to Mankind”
Current Bioactive Compounds Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Current Cancer Drug Targets Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy